Outcomes {12}
Pain, ASIA, pain, neurological deterioration, Cancer
BONE METASTASES, SPINAL CORD, CANCER
The primary outcome is difference in physical functioning four weeks after the start of the treatment (i.e., surgery or radiotherapy) between the intervention and control arm, which will be measured with the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ) Core 15 Palliative Care (C15-PAL) [Secondary outcomes include the following:Pain response at 2, 4, 6, and 8 weeks and 3 monthsDuration of pain relief as measured by the Brief Pain Inventory (BPI) [Change in HRQOL as measured by the EORTC QLQ-C15-PAL and EORTC QLQ Bone Metastases 22 (BM22) from baseline to 4 and 8 weeks and 3 and 6 months [Duration of the hospital stay in daysDays until return to systemic oncological therapy, including hormonal, immune, targeted, and chemotherapyOccurrence of neurological deterioration, defined as deterioration of more than one grade on the American Spinal Cord Injury Association (ASIA) scale as measured by physical examination by a neurologists or trained ASIA physician [Local control according to routine imaging and the electronic patient chartAEs, defined as any undesirable experience occurring to a patient during the study that may be related to the experimental treatment procedureProgression-free survival and overall survivalResource use, such as doctor visits, medication, hospital admissions, and surgical interventions, as well as out-of-pocket expenses such as for over-the-counter drugs and travel costs, will be recorded using the iMTA Medical Consumption Questionnaire (iMCQ) at 3 and 6 months [Cost-effectiveness